Biotech Values

[floblu14]

MNTA European/U.S. Patent Applications Update for RMF - Plus MNTA Overview of their Patent Estate -

1.TISSUE TARGETING 2011-10-20

Abstract:
Methods and compositions related to targeting agents to tumor tissue are described.

http://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20111020&DB=EPODOC&locale=en_EP&CC=WO&NR=2011130697A2&KC=A2

2.SELECTION AND USE OF HOST CELLS FOR PRODUCTION OF GLYCOPROTEINS 2011-10-13

Abstract:
A method of making a glycoprotein having a selected glycostructure.

http://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=0&adjacent=true&locale=en_EP&FT=D&date=20111013&CC=WO&NR=2011127325A1&KC=A1

3.HIGH MANNOSE GLYCANS 2011-10-13

Abstract:
Methods and compositions related to high mannose glycans are described.

http://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=1&adjacent=true&locale=en_EP&FT=D&date=20111013&CC=WO&NR=2011127322A1&KC=A1

4.MS METHODS TO EVALUATE GLYCANS 2011-09-19

Abstract not available for DK 2135091

http://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=2&adjacent=true&locale=en_EP&FT=D&date=20110919&CC=DK&NR=2135091T3&KC=T3

5.GALACTOSE-ALPHA-1, 3-GALACTOSE-CONTAINING N-GLYCANS IN GLYCOPROTEIN PRODUCTS DERIVED FROM CHO CELLS

Abstract:
The present invention provides methods for evaluating a Chinese Hamster Ovary (CHO) cell population by measuring glycans containing terminal galactose-alpha-1-3-galactose residues produced by said cells, wherein the CHO cells have not been genetically engineered to express an alpha-galactosyl transferase coding sequence.

http://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=0&adjacent=true&locale=en_EP&FT=D&date=20100729&CC=CA&NR=2749281A1&KC=A1

6.ISOTOPICALLY-LABELED GLYCANS 2011-09-01

Abstract:
The present disclosure provides methods of making isotopically-labeled glycans or a mixture of glycans (e.g., a glycan preparation) via reductive amination. Such methods are useful, for example, in the determination of the relative amounts of a glycan species present in two or more glycoprotein preparations using mass spectroscopy. In one aspect, the present disclosure provides a method of making an isotopically-labeled glycan by a glycan with an amine and an isotopically-labeled reducing agent to provide an isotopically-labeled aminated glycan. In certain embodiments, the amine is an isotopically-labeled amine.

http://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=1&adjacent=true&locale=en_EP&FT=D&date=20110901&CC=US&NR=2011213137A1&KC=A1

7.METHODS RELATED TO MODIFIED GLYCANS 2011-08-24

Abstract not available

http://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=0&adjacent=true&locale=en_EP&FT=D&date=20110824&CC=EP&NR=2358731A2&KC=A2

8.CHARACTERIZATION OF O-LINKED GLYCANS 2011-08-24

Abstract not available

http://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=1&adjacent=true&locale=en_EP&FT=D&date=20110824&CC=EP&NR=2358760A2&KC=A2


9.EVALUATING HEPARIN PREPARATIONS FOR PHARMACEUTICAL USE
2011-07-20

Abstract:
The disclosure features methods of analyzing preparations of heparin, and materials derived from heparin using strong anion exchange high performance liquid chromatography (SAX-HPLC).

http://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=0&adjacent=true&locale=en_EP&FT=D&date=20110720&CC=EP&NR=2344265A1&KC=A1

10.Evaluating mixtures of low molecular weight heparins by NMR 2011-06-28

Abstract:
Methods for analyzing mixtures of polysaccharides, for example heparin such as enoxaparin are described. In some instances, the mixtures are analyzed using 1D NMR and/or 2D NMR.

http://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&adjacent=true&locale=en_EP&FT=D&date=20110628&CC=US&NR=7968082B1&KC=B1

PATENTS

Over 100 patents give Momenta a strong proprietary position.
Momenta possesses a strong intellectual property position around our characterization platform. We license or own a total of over 100 patents and patent applications. Our patent portfolio includes claims covering:

•methods and technologies for characterizing sugars;
•the use of certain enzymes and reagents that specifically recognize polysaccharides in the characterization of sugars;
•methods and technologies for chemical and metabolic synthesis of sugars;
•the composition of matter of certain novel low-molecular-weight herapins (LMWHs), including M118, and heparinase variants;
•methods to produce and identify sugars associated with glycoproteins;
•methods to analyze and monitor glycoprotein profiles for purposes associated with the diagnosis, staging, prognosis and monitoring of cancer; and
•methods for the in vivo non-invasive delivery of sugars.
We also rely on trade secrets, know-how, continuing technological innovation and in-licensing opportunities to develop and maintain our proprietary position

http://www.momentapharma.com/technology/patents.html